Pathos AI agreed to license up to 500,000 de-identified patient records for Alzheimer's or neurological conditions from Tempus AI under a five-year agreement worth up to $55 million, at 100,000 records per year.

From the articleSEC Filings - Investing.comAlso in AI drug development startup Pathos AI closes $237M investment - SiliconANGLE, Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development | Reuters